Biocon USFDA Approval

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant

In a Q&A, Shreehas Tambe talks about the road ahead for the firm's biosimilars business and how its alliance with Serum is projected to pan out

The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments

The US Food and Drug Administration's (USFDA's) nod to Biocon's supplemental biologics licence application for the new unit will expand the company's capacity multifold, the company said

Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.

We have at least a five-year head start in biosimilars compared with other Indian drugmakers, says Mazumdar-Shaw